Evidence map›Paper›PMID 39772744›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

The single-stranded DNA-binding factor SUB1/PC4 alleviates replication stress at telomeres and is a vulnerability of ALT cancer cells.

Jean-Christophe Dubois, Erin Bonnell, Amélie Filion, Julie Frion, Samuel Zimmer, Muhammad Riaz Khan, Gabriela M Teplitz, Lisa Casimir, Élie Méthot, Isabelle Marois and 4 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. eLife · 2026
    Article
  4. Identification of aFrontiers in pharmacology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jean-Christophe DuboisDépartement de Biologie, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
Erin Bonnell *Aging Research Center of Sherbrooke, Sherbrooke, QC J1H 5N3, Canada.
Amélie Filion *Département de Biologie, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
Julie Frion *Département de Biologie, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.ORCID 0000-0001-9613-799X
Samuel Zimmer *Département de Biologie, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
Muhammad Riaz Khan *Aging Research Center of Sherbrooke, Sherbrooke, QC J1H 5N3, Canada.
Gabriela M TeplitzAging Research Center of Sherbrooke, Sherbrooke, QC J1H 5N3, Canada.
Lisa CasimirDépartement de Biologie, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
Élie MéthotDépartement de Biologie, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
Isabelle MaroisDépartement de Biologie, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
Mouhamed IdrissouDépartement de Biologie, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
Pierre-Étienne JacquesDépartement de Biologie, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.
Raymund J WellingerAging Research Center of Sherbrooke, Sherbrooke, QC J1H 5N3, Canada.
Alexandre MaréchalDépartement de Biologie, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.ORCID 0000-0003-3216-6542

Funding

Canadian Government | Canadian Institutes of Health Research (CIHR) 506663Canadian Government | Canadian Institutes of Health Research (CIHR) FDN154315
6 · The paper itself

Abstract

To achieve replicative immortality, cancer cells must activate telomere maintenance mechanisms. In 10 to 15% of cancers, this is enabled by recombination-based alternative lengthening of telomeres pathways (ALT). ALT cells display several hallmarks including heterogeneous telomere length, extrachromosomal telomeric repeats, and ALT-associated PML bodies. ALT cells also have high telomeric replication stress (RS) enhanced by fork-stalling structures (R-loops and G4s) and altered chromatin states. In ALT cells, telomeric RS promotes telomere elongation but above a certain threshold becomes detrimental to cell survival. Manipulating RS at telomeres has thus been proposed as a therapeutic strategy against ALT cancers. Through analysis of genome-wide CRISPR fitness screens, we identified ALT-specific vulnerabilities and describe here our characterization of the roles of SUB1, a ssDNA-binding protein, in telomere stability. SUB1 depletion increases RS at ALT telomeres, profoundly impairing ALT cell growth without impacting telomerase-positive cells. During RS, SUB1 is recruited to stalled forks and ALT telomeres via its ssDNA-binding domain. This recruitment is potentiated by RPA depletion, suggesting that these factors may compete for ssDNA. The viability of ALT cells and their resilience toward RS also requires ssDNA binding by SUB1. SUB1 depletion accelerates cell death induced by FANCM depletion, triggering unsustainable levels of telomeric damage in ALT cells. Finally, combining SUB1 depletion with RS-inducing drugs rapidly induces replication catastrophe in ALT cells. Altogether, our work identifies SUB1 as an ALT susceptibility with roles in the mitigation of RS at ALT telomeres and suggests advanced therapeutic strategies for a host of still poorly managed cancers.

Indexed as

DNA ReplicationTelomereTelomere HomeostasisCell Line, TumorDNA-Binding ProteinsDNA, Single-StrandedHumansNeoplasmsDNA-Binding ProteinsDNA, Single-Strandedalternative lenghtening of telomeresDNA damageDNA replicationreplication stresstelomeres

Identifiers

PMID39772744
PMCPMC11745411

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.